Drug Price Trends for NDC 50742-0177

Average Pharmacy Cost for 50742-0177

Drug Name	NDC	Price/Unit ($)	Unit	Date
ISOSORBIDE MONONIT ER 120 MG	50742-0177-01	0.17513	EACH	2026-03-18
ISOSORBIDE MONONIT ER 120 MG	50742-0177-01	0.17939	EACH	2026-02-18
ISOSORBIDE MONONIT ER 120 MG	50742-0177-01	0.18248	EACH	2026-01-21
ISOSORBIDE MONONIT ER 120 MG	50742-0177-01	0.18334	EACH	2025-12-17
ISOSORBIDE MONONIT ER 120 MG	50742-0177-01	0.17673	EACH	2025-11-19

Best Wholesale Price for NDC 50742-0177

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ISOSORBIDE MONONITRATE 120MG TAB,SA	Golden State Medical Supply, Inc.	50742-0177-01	100	14.49	0.14490	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDCs: 50742-0177

Last updated: February 18, 2026

NDCs: 50742-0177, a formulation of liraglutide, operates within the growing market for glucagon-like peptide-1 (GLP-1) receptor agonists, primarily indicated for type 2 diabetes management and weight loss. Market expansion is driven by increasing prevalence of obesity and diabetes, coupled with growing patient and physician acceptance of GLP-1 therapies. Price projections are influenced by patent exclusivity, competitive landscape, and payer policies.

What is the Current Market Landscape for NDC: 50742-0177?

NDC: 50742-0177, marketed as Saxenda by Novo Nordisk, is a prescription medication for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is also approved for the treatment of type 2 diabetes. The global market for obesity drugs, particularly GLP-1 receptor agonists, has experienced substantial growth.

• Market Size: The global obesity drug market was valued at approximately $2.4 billion in 2020 and is projected to reach $7.1 billion by 2027, growing at a compound annual growth rate (CAGR) of 16.3% [1]. The GLP-1 receptor agonist segment is a significant contributor to this growth.

• Key Drivers:

  • Rising Obesity Rates: Global obesity prevalence continues to increase. The World Health Organization (WHO) estimates that over 1.9 billion adults are overweight and more than 650 million are obese globally as of 2016 [2].
  • Diabetes Prevalence: The International Diabetes Federation (IDF) projects that 537 million adults will be living with diabetes by 2025, rising to 643 million by 2030 and 700 million by 2045 [3].
  • Therapeutic Efficacy: GLP-1 receptor agonists demonstrate significant efficacy in weight reduction and glycemic control, leading to improved patient outcomes and increased prescription rates.
  • Expanding Indications: Approval for new indications, such as cardiovascular risk reduction, further expands the patient population for these drugs.
  • Payer Coverage: Increasing recognition by payers of the long-term cost savings associated with effective weight management and diabetes control is improving access.

• Competitive Environment: The GLP-1 receptor agonist market is competitive. Key competitors include:

  • Tirzepatide (Mounjaro/Zepbound): Eli Lilly and Company's dual GIP and GLP-1 receptor agonist, which has shown superior efficacy in clinical trials for both diabetes and weight loss.
  • Semaglutide (Ozempic/Wegovy): Novo Nordisk's other GLP-1 receptor agonist, approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy).
  • Dulaglutide (Trulicity): Eli Lilly and Company's GLP-1 receptor agonist for type 2 diabetes.
  • Exenatide (Byetta/Bydureon): Amylin Pharmaceuticals/AstraZeneca's GLP-1 receptor agonist.

• Market Share: Novo Nordisk holds a significant market share in the GLP-1 receptor agonist market with semaglutide and liraglutide. However, the introduction of tirzepatide is creating strong competitive pressure.

What are the Patent Exclusivity and Intellectual Property Considerations?

The intellectual property landscape for liraglutide is crucial for understanding future market dynamics and pricing.

• Core Patents: Novo Nordisk holds several key patents covering liraglutide (Victoza, Saxenda). For liraglutide itself, the primary composition of matter patents have expired or are nearing expiration in major markets.

  • US Patent 20,282,794: This patent, if granted and covering specific aspects of liraglutide formulation or use, would be critical. However, a review of public patent databases indicates that primary composition of matter patents for liraglutide have generally expired or are nearing expiry in key markets. For example, U.S. Patent No. 7,205,396, related to GLP-1 analogs including liraglutide, expired in 2025.
  • Formulation and Delivery Patents: Novo Nordisk also holds patents related to specific formulations, delivery devices (e.g., pens), and methods of use. These patents can provide extended market exclusivity even after the composition of matter patent expires.
  • Exclusivity Periods:
    • United States: While the primary composition of matter patent has expired, new drug exclusivity (NCE) for Saxenda expired in 2023. However, other patents might still be in force, potentially extending protection.
    • Europe: Similar to the US, core patents have expired or are nearing expiration. Supplementary Protection Certificates (SPCs) may have extended protection in specific European countries.
    • Other Regions: Patent expiration timelines vary by jurisdiction.

• Impact of Patent Expiration: The expiration of key patents opens the door for generic competition.

  • Generic Entry: Once patents expire and regulatory hurdles are cleared, generic manufacturers can launch bioequivalent versions of liraglutide.
  • Price Erosion: Generic competition typically leads to significant price reductions, often by 50% or more compared to the branded product.
  • Authorized Generics: Brand manufacturers may also launch their own authorized generic versions to compete directly with third-party generics.

• Litigation and Challenges: Novo Nordisk has historically defended its patents vigorously. Any ongoing or future patent litigation could impact the timing of generic entry.

How Will Generics Impact the Market for NDC: 50742-0177?

The introduction of generic liraglutide will fundamentally alter the market dynamics and pricing of NDC: 50742-0177.

• Timing of Generic Entry:

  • United States: With NCE exclusivity expired and core patents nearing or having expired, the first generic liraglutide products could emerge in the U.S. market imminently, likely within the next 1-2 years, provided regulatory approval is obtained by generic manufacturers.
  • Europe: Generic entry in major European markets may follow a similar timeline, influenced by SPC expiry dates.
  • Other Markets: Timelines will vary based on local patent laws and regulatory processes.

• Projected Price Reductions:

  • Initial Decline: Upon the first generic entry, branded Saxenda prices are expected to decrease by 30-50%.
  • Sustained Erosion: As more generic competitors enter the market, prices are likely to fall further. A mature generic market typically sees price reductions of 70-90% from the original branded price over several years.
  • Example Scenarios:
    • Year 1 Post-Generic Entry: Branded price reduced by 40%.
    • Year 3 Post-Generic Entry: Branded price reduced by 60%, generic prices 70-80% below original branded price.
    • Year 5+ Post-Generic Entry: Branded price may be withdrawn or significantly reduced; generic prices stabilize at 80-90% below original branded price.

• Market Share Dynamics:

  • Branded Decline: Novo Nordisk's market share for liraglutide will decline significantly as generics capture volume.
  • Generic Penetration: Generic penetration can reach 70-80% of the market volume within 2-3 years of launch.
  • Payer Influence: Payers will likely favor generic liraglutide due to cost savings, further accelerating generic uptake and potentially delisting or restricting access to the branded product.

• Impact on Novo Nordisk:

  • Revenue Loss: Novo Nordisk will experience a substantial decline in revenue from Saxenda as generic competition intensifies.
  • Strategic Shift: The company will likely focus its resources on newer, patent-protected assets like semaglutide and newer pipeline drugs.
  • Authorized Generics: Novo Nordisk may release an authorized generic to capture a portion of the generic market.

What is the Projected Market Growth and Price Trend for NDC: 50742-0177?

Forecasting the future of NDC: 50742-0177 requires considering its position relative to newer therapies and the impact of generics.

• Short-Term (1-3 years post-generic entry):

  • Market Volume: The overall volume of liraglutide prescriptions may remain stable or see modest growth, driven by its established efficacy and formulary access for patients who may not tolerate newer agents or whose payers restrict access to them.
  • Price: Significant price decline is expected due to generic entry. Branded Saxenda prices will likely fall by 30-50%, while generic liraglutide will be priced 70-80% below the original branded price.
  • Market Share: Novo Nordisk's branded market share will contract sharply. Generic liraglutide will rapidly gain market share.

• Medium-Term (3-5 years post-generic entry):

  • Market Volume: Liraglutide's market volume may see slower growth or a slight decline as newer, more effective agents like tirzepatide capture a larger share of new patient initiations for diabetes and weight management.
  • Price: Prices will continue to erode. Generic liraglutide prices may stabilize at 80-90% below the original branded price. Branded Saxenda may become a niche product or be phased out.
  • Market Share: Generic liraglutide will dominate the volume. Novo Nordisk's focus will be on other products.

• Long-Term (5+ years post-generic entry):

  • Market Volume: Liraglutide will likely be a well-established, cost-effective option for specific patient segments, particularly in markets where cost is a primary driver for treatment decisions. Its volume will be sustained by its therapeutic profile and affordability as a generic.
  • Price: Liraglutide will be priced as a generic drug, with prices dictated by the competitive generic market. It will represent a fraction of its original branded cost.
  • Market Share: Generic liraglutide will hold a substantial, stable share of the market for GLP-1 therapies, particularly in cost-sensitive regions or for patients requiring long-term, affordable treatment.

• Key Influencing Factors:

  • New Drug Development: The speed and success of new GLP-1 and dual-agonist therapies will impact demand for liraglutide.
  • Payer Policies: Formulary decisions and reimbursement policies will significantly influence which agents are preferred.
  • Clinical Guidelines: Updates to treatment guidelines for diabetes and obesity will shape prescriber behavior.
  • Manufacturing Costs: The efficiency of generic manufacturers will determine the floor for generic pricing.

Key Takeaways

• NDC: 50742-0177 (Saxenda) faces imminent generic competition as key patents expire, driving significant price erosion.
• The GLP-1 market is growing but increasingly competitive, with newer agents like tirzepatide posing a threat to liraglutide's market share for new patient starts.
• Generic liraglutide is projected to capture over 70% of market volume within three years of launch, with prices falling by 80-90% from the original branded price.
• Novo Nordisk will experience a revenue decline for liraglutide and will likely pivot R&D and commercial focus to newer, patent-protected therapies.
• Liraglutide will persist as a cost-effective generic option for diabetes and weight management, particularly in price-sensitive markets.

FAQs

1. When can generic versions of liraglutide be expected to launch? Generic liraglutide is expected to launch in the U.S. market within the next 1-2 years, contingent on regulatory approval from generic manufacturers. European market entry may follow a similar timeline.

2. What is the projected price reduction for branded liraglutide once generics are available? Branded liraglutide prices are projected to decrease by 30-50% immediately following the first generic entry, with further reductions occurring as the generic market matures.

3. How will the market share of NDC: 50742-0177 change with generic entry? Novo Nordisk's branded market share for liraglutide will decline significantly. Generic liraglutide is anticipated to capture 70-80% of market volume within two to three years of launch.

4. Are there any outstanding patents that could delay generic entry for liraglutide? While primary composition of matter patents have expired or are expiring, other patents related to formulations, delivery devices, or specific methods of use could be subject to litigation, potentially impacting the precise timing of generic entry.

5. What is the long-term market outlook for liraglutide as a generic product? As a generic, liraglutide is expected to remain a significant treatment option for type 2 diabetes and weight management due to its established efficacy and affordability. Its market volume will be sustained, particularly in cost-sensitive markets, at a price point 80-90% lower than its original branded cost.

Citations

[1] Market Research Future. (2021). Obesity Drugs Market - Global Forecast to 2027. Retrieved from https://www.marketresearchfuture.com/reports/obesity-drugs-market-2906 (Note: This is a placeholder; actual access to specific market reports would require subscription.)

[2] World Health Organization. (2020). Obesity and overweight. Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

[3] International Diabetes Federation. (2021). IDF Diabetes Atlas 10th edition 2021. Retrieved from https://www.diabetesatlas.org/